Page last updated: 2024-12-05

fenoldopam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenoldopam is a selective dopamine D1 receptor agonist that acts as a potent vasodilator. It is used intravenously to treat severe hypertension, especially hypertensive emergencies. Fenoldopam was synthesized by researchers at the Upjohn Company in the 1970s. Its mechanism of action involves binding to D1 receptors in vascular smooth muscle, leading to relaxation and dilation of blood vessels, thereby reducing blood pressure. The drug is known to have a rapid onset of action and a short duration of effect. Fenoldopam's unique selectivity for D1 receptors makes it a valuable tool for studying the role of dopamine in cardiovascular regulation. Its therapeutic effects and relatively low side effects profile have made it a widely studied compound in various clinical settings. Research continues to explore its potential applications in other conditions, such as heart failure and kidney disease.'

Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3341
CHEMBL ID588
CHEBI ID5002
SCHEMBL ID34250
SCHEMBL ID13287212
MeSH IDM0028173

Synonyms (72)

Synonym
sk-82526-j
AB00698256-15
BRD-A50684349-001-01-5
gtpl939
LOPAC0_000556
1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-
fenoldopam [inn:ban]
fenoldopamum [latin]
sk&f-82526
skf 82526
BIOMOL-NT_000042
PDSP1_001661
PDSP2_001645
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
fenoldopamum
CHEBI:5002 ,
smr000469190
MLS001401388 ,
C07693 ,
fenoldopam
67227-56-9
DB00800
NCGC00025246-03
BPBIO1_001265
NCGC00025246-02
HMS2090G16
NCGC00015444-05
L000254
carlacor
sk-82526
CHEMBL588
fenoldopam (inn)
carlacor (tn)
D07946
9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
NCGC00015444-04
unii-inu8h2kawg
inu8h2kawg ,
tox21_110152
cas-67227-56-9
dtxsid0043896 ,
dtxcid8023896
CCG-204646
NCGC00015444-06
NCGC00015444-03
FT-0641107
AKOS015906543
fenoldopam [who-dd]
fenoldopam [mi]
fenoldopam [vandf]
fenoldopam [inn]
HY-B0735
AB00698256-13
SCHEMBL34250
NCGC00015444-07
tox21_110152_1
9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;mesylic acid
bdbm60917
cid_49659
9-chloranyl-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;methanesulfonic acid
SCHEMBL13287212
AB00698256_16
HMS3715H14
1092382-99-4
Q2357007
BRD-A50684349-003-01-1
SDCCGSBI-0050539.P002
NCGC00015444-17
HMS3742O09
EN300-119508
c01ca19
fenoldopamum (latin)

Research Excerpts

Overview

Fenoldopam is a selective dopamine-1 receptor agonist that improves diuresis by increasing renal blood flow and perfusion and causing peripheral vasodilation. It has been suggested to be a possible reno-protective agent in patients undergoing cardiac surgery.

ExcerptReferenceRelevance
"Fenoldopam is an approved drug used to treat hypotension. "( A positive-negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats.
Du, T; Gao, S; Hu, M; Liang, D; Moatamed, L; Siddiqui, N; Sun, R; Zhang, Y, 2021
)
2.3
"Fenoldopam mesylate is a selective agonist of DA-1 receptors. "( Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury.
Busca, A; Di Daniele, N; Ferrannini, M; Gola, C; Marrone, G; Noce, A; Rovella, V, 2019
)
3.4
"Fenoldopam is a selective dopamine-1 receptor agonist with renoprotective properties."( Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis.
Gillies, MA; Honoré, PM; Kakar, V; Ostermann, M; Parker, RJ, 2015
)
2.58
"Fenoldopam is a selective dopamine-1 receptor agonist that improves diuresis by increasing renal blood flow and perfusion and causing peripheral vasodilation. "( The pharmacokinetics of intravenous fenoldopam in healthy, awake cats.
Court, MH; Labato, MA; O'Neill, KE, 2016
)
2.15
"Fenoldopam mesylate is a short-acting dopamine-1 agonist that has been suggested to be a possible reno-protective agent in patients undergoing cardiac surgery. "( Effects of fenoldopam infusion in complex cardiac surgical operations: a prospective, randomized, double-blind, placebo-controlled study.
Ballotta, A; Bianchini, C; Castelvecchio, S; De Benedetti, D; Frigiola, A; Menicanti, L; Ranucci, M, 2010
)
2.19
"Fenoldopam is a selective dopamine-1 receptor agonist that causes peripheral arterial vasodilation, increased renal blood flow, and diuresis. "( Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs.
Bloom, CA; Court, MH; Hazarika, S; Labato, MA, 2012
)
2.06
"1. Fenoldopam is a dopamine-like receptor agonist that selectively increases renal medullary blood flow. "( Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk.
Hassanin, A; Kirtane, AJ; Leon, MB; Mehran, R; Moses, JW; Talati, S; Weisz, G, 2012
)
1.33
"Fenoldopam is a short-acting dopamine-1 receptor agonist that might provide renal protection during ischemic stress. "( Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial.
Bonilla, AM; Campbell, SC; Fergany, AF; Gill, IS; Kaouk, JH; Kaple, KM; Mahboobi, R; Mascha, EJ; Novak, SM; O'Hara, JF; Sessler, DI; Ziegman, SA, 2013
)
3.28
"Fenoldopam is a selective dopamine-receptor agonist with renoprotective properties."( Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
Madyoon, H, 2001
)
1.31
"Fenoldopam is a dopamine receptor alpha1-specific agonist that increases renal blood flow in patients with kidney failure."( Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
Cotsonis, G; Finkel, KW; Murray, PT; Samuels, J; Shaw, AD; Tumlin, JA, 2005
)
2.49
"Fenoldopam is a selective dopamine1 (DA1) receptor agonist, most of the activity of which resides in the R-enantiomer, which also shows weaker alpha 2-adrenoceptor antagonist activities."( Dopamine "renal dose" versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation.
Beatini, M; Bertocchi, M; Bonifazio, L; Fontana, I; Fontana, S; Germi, MR; Ghinolfi, D; Ornis, S; Porcile, E; Saltalamacchia, L; Valente, U,
)
1.14
"Fenoldopam mesylate is a selective dopamine-1 agonist, with no effect on dopamine-2 and alpha1 receptors, producing a selective renal vasodilation. "( A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
Ancona, G; Bortone, D; Brienza, N; Bruno, F; Dalfino, L; Faconda, G; Fiore, T; Guagliardi, C; Malcangi, V; Ribezzi, M; Trerotoli, P, 2006
)
2.1
"Fenoldopam mesylate is a potent dopamine A-1 receptor agonist that increases blood flow to the renal cortex and outer medulla."( Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.
Biondi-Zoccai, GG; Bove, T; Calabrò, MG; De Luca, M; Landoni, G; Ranucci, M; Tumlin, JA; Zangrillo, A, 2007
)
1.38
"Fenoldopam is a drug specific to dopamine-1 receptors in the kidneys."( Current literature questions the routine use of low-dose dopamine.
Abay, MC; Everts, K; Reyes, JD; Wisser, J, 2007
)
1.06
"Fenoldopam is a selective DA1 agonist with potential nephroprotective capabilities. "( Fenoldopam vs dopamine as a nephroprotective strategy during living donor kidney transplantation: preliminary data.
Belluoccio, AA; Cutuli, M; Gagliano, M; Macarone, M; Mangianeli, S; Mistretta, G; Morello, G; Paratore, A; Sorbello, M; Veroux, M; Veroux, P,
)
3.02
"Fenoldopam (SK&F 82526) is a selective (DA1) dopamine-receptor agonist."( Cardiovascular dopamine receptors: recent advances in agonists and antagonists of the DA1-receptor.
Berkowitz, BA; Ohlstein, EH, 1984
)
0.99
"Fenoldopam is a selective agonist of peripheral dopaminergic (DA-1) receptors and has been shown to improve blood flow and lower blood pressure."( High-performance liquid chromatographic determination of the N-ethyl tricarbamate ester pro-drug of fenoldopam utilizing simultaneous post-column hydrolysis and fluorescence derivatization.
Boppana, VK; Miller-Stein, C; Rhodes, GR, 1994
)
1.23
"Fenoldopam is an effective drug for reducing BP following hypertensive episodes in the postoperative setting. "( Fenoldopam infusion for the treatment of postoperative hypertension.
Cantillo, J; Goldberg, ME; Muñoz, R; Nemiroff, MS; Schieren, H; Subramoni, J; Torjman, M,
)
3.02
"Fenoldopam is a racemic mixture (R-FEN, S-FEN) that is a selective dopamine (DA-1) receptor agonist with pronounced cardiovascular and renal effects in humans. "( Stereoselective metabolism of fenoldopam and its metabolites in human liver microsomes, cytosol, and slices.
Collins, JM; Klecker, RW, 1997
)
2.03
"Fenoldopam is a dopamine agonist that causes peripheral vasodilation via stimulation of dopamine 1 (D1) receptors. "( Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.
Brogden, RN; Markham, A, 1997
)
3.18
"Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. "( Fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies.
Frishman, WH; Post, JB, 1998
)
3.19
"Fenoldopam seems to be an efficient alternative to nifedipine, especially because of its more rapid onset of action."( DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension.
Berger, J; Gombotz, H; Mahla, E; Metzler, H; Plaza, J, 1998
)
2.04
"Fenoldopam is a dopamine receptor (DA1 selective) agonist that is a systemic and renal vasodilator."( Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises.
Aronson, S; Deeb, GM; Epstein, M; Levy, JH; Luther, RR; Oparil, S; Prielipp, R; Taylor, A, 1999
)
2.47
"Fenoldopam is a new, selective, dopamine-1 receptor agonist that causes both systemic and renal arteriolar vasodilation."( The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.
Anjum, S; Epstein, M; Fellmann, J; Lambrecht, LJ; Luther, RR; Mathur, VS; McGuire, D; Swan, SK, 1999
)
1.38
"Fenoldopam is a dopamine1 agonist whose pharmacological effects include vasodilation of the vascular beds of the kidney, mesentery, skeletal muscle, and coronary systems, resulting in a decrease in systemic vascular resistance and mean arterial pressure. "( Fenoldopam for controlled hypotension during spinal fusion in children and adolescents.
Tobias, JD, 2000
)
3.19
"Fenoldopam is a direct-acting vasodilator that acts at the postsynaptic dopamine 1 receptors in renal, coronary, cerebral, and splanchnic vasculature resulting in arterial dilation and a lowering of the mean arterial pressure (MAP). "( Initial experience with fenoldopam in children.
Pruitt, RD; Strauser, LM; Tobias, JD, 1999
)
2.05
"Fenoldopam mesylate is a novel, highly selective dopamine type-1 agonist that preferentially dilates the renal and splanchnic vasculature, but has not been investigated in patients undergoing prolonged aortic clamping for whom adverse renal outcomes should be more likely."( Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair.
Benjamin, ME; Flinn, WR; Gilbert, TB; Hasnain, JU; Lilly, MP, 2001
)
2.47
"Fenoldopam is a novel dopamine-1 receptor selective agonist that can be used as a vasodilator perioperatively to treat hypertension and to produce induced hypotension. "( Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside.
Benson, KT; Goto, H; Iwasawa, K; Kindscher, JD; Narita, H; Yakazu, Y, 2001
)
2.02
"Fenoldopam is an interesting orphan drug that is a variant of dopamine. "( Preventing contrast-induced nephropathy with fenoldopam.
Bjarnason, H; Chamsuddin, A; Hunter, DW; Kowalik, K, 2001
)
2.01
"Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow (RPF) in patients with normotensive and hypertensive conditions."( Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
Mathur, VS; Murray, PT; Tumlin, JA; Wang, A, 2002
)
2.48
"Fenoldopam is a new vasodilator undergoing clinical trials for the treatment of hypertensive emergencies. "( 5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle.
Gretler, DD; Jones, KC; Murphy, MB, 1992
)
1.96
"Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation."( Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.
Aronson, S; Glock, D; Goldberg, LI; Moss, J; Roizen, MF; Roth, S, 1990
)
1.24
"Fenoldopam is a selective dopamine1 (DA1) receptor agonist. "( The pharmacology of fenoldopam.
Brooks, DP; Nichols, AJ; Ruffolo, RR, 1990
)
2.05
"Fenoldopam (SK&F 82526) is a short-acting selective dopamine-1 agonist in clinical trials for the treatment of hypertension, congestive heart failure and renal failure. "( Identification of fenoldopam prodrugs with prolonged renal vasodilator activity.
Brooks, DP; Bryant, MA; Chambers, PA; Cyronak, MJ; DePalma, PD; Erhard, KF; Gaitanopoulos, DE; Karpinski, K; Mico, B; Weinstock, J, 1990
)
2.06
"Fenoldopam (SK&F 82526) is a potent and selective dopamine DA-1 agonist with demonstrated renal vasodilator and antihypertensive activities in experimental animals and humans. "( Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
Horner, E; Kinter, LB; Mann, WA; Ruffolo, RR; Weinstock, J, 1990
)
1.97
"Fenoldopam (SKF 82526 J) is a selective DA-1 receptor agonist and thus of a potential benefit for promoting afterload reduction, renal vasodilatation, and diuresis in congestive heart failure. "( Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure.
Jover, BF; McGrath, BP, 1988
)
2.03
"Fenoldopam mesylate (FM) is a dopaminergic vasodilator with demonstrated efficacy and a favourable safety profile in hypertensive and congestive heart failure patients. "( Ultrastructure of an arterial lesion induced in rats by fenoldopam mesylate, a dopaminergic vasodilator.
Arena, E; Berkowitz, BA; Bugelski, PJ; Morgan, DG; Sowinski, JM; Vockley, CM, 1989
)
1.97
"Fenoldopam (SKF-82526-J) is a new, orally available, selective, dopamine-receptor agonist with potent renal vasodilating properties (six times that of dopamine) without positive inotropic or adrenergic activity."( Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure.
Aronoff, RD; Leon, CA; Pratt, CM; Roberts, R; Suarez, JM; Young, JB, 1985
)
1.23
"Fenoldopam (SK&F 82526) is a potent agonist at DA1 receptors, with much less agonist activity at the DA2 subtype or at alpha and beta adrenoceptors."( Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
Blumberg, AL; DeMarinis, RM; Harvey, CA; Hieble, JP; Owen, DA; Valocik, RE, 1987
)
0.99

Effects

Fenoldopam has no dopamine-2, alpha or beta-adrenergic activity and is 3.5 times more potent than dopamine in dilating renal vessels. FenoldopAm has served as an excellent model compound for comparison of metabolism in human liver slices with metabolism in subcellular fractions.

ExcerptReferenceRelevance
"Fenoldopam has been shown to induce diuresis and be well-tolerated in healthy cats."( The pharmacokinetics of intravenous fenoldopam in healthy, awake cats.
Court, MH; Labato, MA; O'Neill, KE, 2016
)
1.43
"Fenoldopam has served as an excellent model compound for comparison of metabolism in human liver slices with metabolism in subcellular fractions."( Stereoselective metabolism of fenoldopam and its metabolites in human liver microsomes, cytosol, and slices.
Collins, JM; Klecker, RW, 1997
)
1.31
"Fenoldopam has no dopamine-2, alpha or beta-adrenergic activity and is 3.5 times more potent than dopamine in dilating renal vessels."( [Fenoldopam: potential clinical applications in heart surgery].
Shorten, GD, 2001
)
1.94

Actions

Fenoldopam seems to increase the renal flow directed to the most external kidney areas. Activity was mediated by protein kinase A (PKA) since it was blocked by the PKA antagonist Rp-8-CTP-adenosine cyclic 3':5'-monophosphorothioate.

ExcerptReferenceRelevance
"Fenoldopam seems to increase the renal flow directed to the most external kidney areas."( The effect of various fenoldopam doses on renal perfusion in patients undergoing cardiac surgery.
Cirri, S; Meco, M, 2010
)
1.4
"The fenoldopam-induced increase in PLC-gamma and activity was mediated by protein kinase A (PKA) since it was blocked by the PKA antagonist Rp-8-CTP-adenosine cyclic 3':5'-monophosphorothioate (Rp-8-CTP-cAMP-S) and mimicked by direct stimulation of adenylyl cyclase with forskolin or by a PKA agonist, Sp-cAMP-S."( Dopamine D1A receptor regulation of phospholipase C isoform.
Eisner, GM; Felder, RA; Jose, PA; Mouradian, MM; Yamaguchi, I; Yu, PY, 1996
)
0.77
"fenoldopam produced an increase in PRA which was again blocked by SCH 23390."( Increase in plasma renin activity evoked by fenoldopam in dogs is directly mediated by dopamine1 receptor stimulation.
Cavero, I; Katchadourian, P; Montier, F; Pratz, J, 1989
)
1.26

Treatment

Fenoldopam significantly decreased serum glucose, insulin, cholesterol, triglyceride, urea, creatinine, and blood pressure. Treatment with fenoldOpam increased renal blood flow in comparison to that in the control group ( p = 0.03).

ExcerptReferenceRelevance
"Fenoldopam pre-treatment decreased the responsiveness to subsequent fenoldopam stimulation (t(1/2) approximately equal to 20 min) with complete desensitization at 30 minutes."( Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4.
Bengra, C; Felder, RA; Jose, PA; Watanabe, H; Xu, J, 2002
)
1.04
"Fenoldopam treatment significantly increased urine output as well as urinary sodium indicating reduced sodium retention."( Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats.
Goyal, RK; Umrani, DN, 2003
)
2.48
"Fenoldopam treatment significantly reduced BP to the therapeutic goal in 8 of 8 patients; placebo reduced BP to this goal in only 4 of 8 patients (p < 0.05)."( Fenoldopam infusion for the treatment of postoperative hypertension.
Cantillo, J; Goldberg, ME; Muñoz, R; Nemiroff, MS; Schieren, H; Subramoni, J; Torjman, M,
)
2.3
"Fenoldopam treatment significantly reduced fasting but not fed blood glucose levels and lowered the blood pressure in diabetic animals."( Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats.
Goyal, RK; Umrani, DN, 2002
)
1.35
"Treatment with fenoldopam significantly decreased serum glucose, insulin, cholesterol, triglyceride, urea, creatinine, and blood pressure."( Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats.
Goyal, RK; Umrani, DN, 2003
)
2.1
"Treatment with fenoldopam increased renal blood flow in comparison to that in the control group ( p = 0.03)."( The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping.
Bird, ET; Cohn, EJ; Harlin, SA; Harre, JG; Hogan, MB; Holmes, GF; Miller, ML; Miller, Q; Peyton, BD; Riley, KD; Taylor, A, 2003
)
0.95
"Treatment with fenoldopam prevented activation of NF-kappaB DNA binding activity (p < 0.001) and attenuated 72 of 75 I/R-induced genes and 3 of 8 I/R-suppressed genes."( Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure.
Aravindan, N; Natarajan, M; Shaw, AD, 2006
)
2.12
"Treatment with fenoldopam significantly reduced (P < 0.001) I/R-induced apoptosis both in the cortex and medulla and attenuated all 73 I/R-induced apoptosis-related genes."( Effect of fenoldopam on ischemia/reperfusion-induced apoptosis.
Aravindan, N; Cata, JP; Dougherty, PM; Shaw, AD, 2006
)
1.08
"Treatment with fenoldopam or placebo was initiated immediately after other causes of hypertension had been ruled out. "( Fenoldopam infusion for the treatment of postoperative hypertension.
Cantillo, J; Goldberg, ME; Muñoz, R; Nemiroff, MS; Schieren, H; Subramoni, J; Torjman, M,
)
1.93

Toxicity

ExcerptReferenceRelevance
" TRT, the delivery of therapeutic agents directly to the kidneys by renal arterial infusion, has the advantage of providing a higher local effective dose with potentially greater renal effects, while limiting systemic adverse effects due to renal first-pass elimination."( Safety and performance of targeted renal therapy: the Be-RITe! Registry.
Allie, DE; Cohen, MG; Danna, P; Fearon, WF; Filby, SJ; Findeiss, L; Kyriazis, D; Leon, MB; Mehran, R; Moses, JW; Price, MJ; Sachdev, N; Teirstein, PS; Vora, K; Walker, CM; Weinstock, BS; Weisz, G; Wiechmann, BN, 2009
)
0.35

Pharmacokinetics

Enthusiasm exists for the use of fenoldopam in nonpolyuric kidney injury in dogs, although pharmacokinetic data are lacking. We developed and validated a rapid, selective, and sensitive ultra-performance liquid-chromatography mass-spectrometry (UPLC-MS/MS) method.

ExcerptReferenceRelevance
"1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension."( Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.
Frederickson, ED; Goldberg, LI; McCoy, CE; Murphy, MB; Weber, RR; Ziemniak, JA, 1988
)
0.77
" Enthusiasm exists for the use of fenoldopam in nonpolyuric kidney injury in dogs, although pharmacokinetic data are lacking."( Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs.
Bloom, CA; Court, MH; Hazarika, S; Labato, MA, 2012
)
0.9
"We developed and validated a rapid, selective, and sensitive ultra-performance liquid-chromatography mass-spectrometry (UPLC-MS/MS) method for quantifying fenoldopam in human plasma for pharmacokinetic studies."( Rapid determination of fenoldopam in human plasma by UPLC-MS/MS for pharmacokinetic analysis in patients.
Deng, C; He, G; Lin, Q; Mai, L; Shan, Z; Wang, X; Yang, M; Yu, X; Zheng, Z; Zhong, S; Zhou, Z, 2015
)
0.93
" The pharmacokinetics in healthy beagle dogs has been reported; however, pharmacokinetic data in cats are lacking."( The pharmacokinetics of intravenous fenoldopam in healthy, awake cats.
Court, MH; Labato, MA; O'Neill, KE, 2016
)
0.71
" The purpose of this study is to develop and validate an LC-MS method to quantify fenoldopam and its major metabolites fenoldopam-glucuronide and fenoldopam-sulfate in plasma and apply the method to a pharmacokinetic study in rats."( A positive-negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats.
Du, T; Gao, S; Hu, M; Liang, D; Moatamed, L; Siddiqui, N; Sun, R; Zhang, Y, 2021
)
1.08

Compound-Compound Interactions

ExcerptReferenceRelevance
") was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine."( Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.
Glock, D; Goldberg, LI; Lass, NA, 1988
)
0.49

Bioavailability

ExcerptReferenceRelevance
" Compared with fasting, bioavailability of fenoldopam was decreased significantly when administered with food: mean peak plasma fenoldopam level decreased from 26."( The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991
)
0.78
" Lack of oral bioavailability has limited its use in long-term therapy, however; levodopa and dopa conjugates which are orally absorbed and metabolized to the active form are under investigation."( Dopamine and dopamine receptor agonists in cardiovascular therapy.
Elliott, WJ; Murphy, MB, 1990
)
0.28
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia. The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fen oldopam may have a role where parenteral treatment of hypertension is required.

ExcerptRelevanceReference
" The increase in ERPF was not maintained to the end of the dosing interval during chronic administration, probably due to the short half-life of fenoldopam."( Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients.
Audet, P; Dafoe, D; Hedrich, D; Ilson, B; Jorkasky, DK; Shusterman, N; Stote, RM, 1992
)
1.93
" Dose-response studies between 10(-8) and 10(-4)M concentrations were performed for all drugs."( In vitro responses of equine digital vessels to dopamine and fenoldopam.
Baxter, GM; Moore, JN; Tackett, RL, 1991
)
0.52
" Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia."( A single dose study of the effects of fenoldopam and enalapril in mild hypertension.
Freestone, S; Jeffrey, RF; Lee, MR; MacDonald, TM, 1991
)
1.46
" Incubation of DA with increasing concentrations of fenoldopam produced parallel rightward shifts in the DA dose-response curves."( Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
Grenader, A; Healy, DP, 1991
)
1.97
" Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside."( Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension.
Elliott, WJ; Fumo, MT; Gretler, DD; McCray, GR; Murphy, MB; Nelson, KS; Oliner, CM; Weber, RR, 1990
)
1.45
" In the unblocked group, after PGF2 alpha vasoconstriction, fenoldopam infusion resulted in a dose-dependent decrease in the mean pulmonary arterial pressure with a dose-response curve characteristic for a drug-receptor interaction [Response = -1."( Effect of fenoldopam on preconstricted isolated salt-perfused rat lungs.
Bucciarelli, RL; Drummond, W; Gause, GE; Knight, ME; Polak, MJ, 1989
)
0.92
" A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug."( Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Hasenfuss, G; Just, H, 1989
)
0.28
" Mean diastolic blood pressure fell by 10 mm Hg, 45 min after oral dosing and then gradually returned to baseline values."( The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.
Brown, J; Harvey, JN; Lee, MR; Worth, DP, 1985
)
0.6
" The effects of chronic acetaminophen dosing (1000 mg three times/day for 7 days) on a single 100 mg tablet of fenoldopam were studied in a second crossover study in seven additional volunteers."( The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation.
Allison, N; Boppana, VK; Dubb, J; Stote, R; Ziemniak, JA, 1987
)
0.74
" These findings suggest that in humans, fenoldopam may acutely override the dopaminergic antagonism of metoclopramide given in clinical dosage and that its cardiovascular and renal effects are not prostaglandin-mediated."( Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
Glück, Z; Gnädinger, MP; Jossen, L; Peheim, E; Weidmann, P, 1987
)
0.76
" After the administration of SK&F R-83566, the renal vasodilator responses to fenoldopam were antagonized markedly with an approximate 30-fold rightward shift in the log dose-response curve, whereas the renal vasodilator responses to dopamine were abolished completely and converted into small vasoconstrictor responses."( Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
Nichols, AJ; Ruffolo, RR; Shebuski, RJ; Smith, JM, 1987
)
0.72
" 3 Propranolol, but not domperidone, shifted to the right the dose-response curve for the positive inotropic and chronotropic effects of dopamine."( The lack of the effect of DA-1 and DA-2 dopamine agonists on the isolated guinea-pig atria.
Martinez-Mir, I; Morales-Olivas, FJ; Rubio, E, 1987
)
0.27
" In 15 patients with a mean radionuclide ejection fraction of 17%, the agents were infused in a random-ordered, double-blinded, crossover, active drug-controlled protocol after optimal dosing was determined during a titration period."( Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside.
Kingry, C; Leon, CA; Pratt, CM; Roberts, R; Taylor, AA; Young, JB, 1988
)
0.65
" 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required."( Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.
Frederickson, ED; Goldberg, LI; McCoy, CE; Murphy, MB; Weber, RR; Ziemniak, JA, 1988
)
0.72
" The displacements of the dose-response curves for fenoldopam, dopexamine and dopamine were, however, non-parallel with significant depression of the maxima to 30."( Atypical antagonism of D1-receptor-mediated vasodilator response in the perfused kidney by SCH23390.
Broadley, KJ; Martin, SW, 1995
)
0.54
" alpha-Adrenoceptor blockade by dopexamine and fenoldopam was confirmed by the parallel displacement of dose-response curves for the vasopressor responses to noradrenaline."( Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.
Broadley, KJ; Martin, SW, 1995
)
0.82
" In the presence of 200 microM Rp-cAMPS, the dose-response curves of the dopamine D1 receptor agonists SKF 38393 and fenoldopam were shifted to the left and maximal agonist responses were markedly increased."( Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices.
Friedman, E; Undie, AS, 1994
)
0.5
" Although carotid arterial pressure did not change significantly after administration of fenoldopam at the dosage of 3 mg/kg, administration of fenoldopam at the dosages of 6 and 9 mg/kg significantly reduced carotid arterial pressure from 113 +/- 10 to 88 +/- 3 and 81 +/- 5 mm of Hg, respectively."( Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
Eades, SC; Moore, JN, 1993
)
0.51
"Prospective, unblinded, dose-response evaluation in an awake animal."( Dopaminergic receptor-mediated effects in the mesenteric vasculature and renal vasculature of the chronically instrumented newborn piglet.
Barrington, KJ; Cheung, PY; Jirsch, DW; Pearson, RJ, 1996
)
0.29
" This drug dosage was selected to produce a 25-30% increase in cardiac output by all three drugs during control conditions."( Effects of fenoldopam on systemic and splanchnic haemodynamics and oxygen delivery/consumption relationship during hyperdynamic ovine endotoxaemia.
Morel, DR; Schiffer, ER; Schwieger, IM, 1998
)
0.69
"cm-5) were noted in both groups, whereby in the F group the therapeutic goal could be achieved more quickly with the dosage regimen chosen."( DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension.
Berger, J; Gombotz, H; Mahla, E; Metzler, H; Plaza, J, 1998
)
0.59
" As an active control, we used an equivalent antihypertensive dosage of captopril (10 mg/kg)."( Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats.
de Jong, PE; de Vries, PA; de Zeeuw, D; Kluppel, CA; Navis, G, 1999
)
0.3
" The possible applications of fenoldopam and suggested dosing regimens in children are reviewed."( Initial experience with fenoldopam in children.
Pruitt, RD; Strauser, LM; Tobias, JD, 1999
)
0.9
" The dissociation constant (K(B)) and relative intrinsic efficacy (E(r)) for each partial agonist were calculated using a partial agonist interaction null model in which the effects of fixed concentrations of each partial agonist on the dopamine dose-response curve were evaluated."( Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
Abell, C; Avalos, M; Kwan, SW; Mak, C; Randall, PK; Trzeciakowski, JP; Wilcox, RE,
)
0.13
"L-1) shifted the dose-response curves to the right in a nonparallel fashion and decreased the maximal response (Emax) of both the fenoldopam(FODA, a selective DA1 agonist)-induced and the propyl-buty-dopamine(PBDA, a selective DA2 agonist)-induced vasorelaxation showing a non-competitive antagonistic action."( [Effects of l-stepholidine on the peripheral vascular dopamine DA1 and DA2 receptor subtypes].
Guo, W; Jin, G; Zhang, W; Zhao, R; Zhi, J, 1998
)
0.5
" Of seven prospective studies using various dosing regimens of N-acetylcysteine, four revealed beneficial results."( Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Brokering, KL; Theobald, JC; Walker, PD, 2003
)
1.76
" Each group received dobutamine (5 microg x kg(-1) x min(-1)), and the dosage of norepinephrine was adjusted to achieve a mean arterial pressure between 70 and 80 mmHg."( Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock.
Coluzzi, F; Conti, G; De Gaetano, A; Morelli, A; Orecchioni, A; Pelaia, P; Pietropaoli, P; Rocco, M; Vernaglione, E, 2004
)
0.64
" Median contrast dosage was 120 mL (range 50-200)."( Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial.
Allie, DE; Hebert, CJ; Keller, VA; Lirtzman, MD; Mitran, EV; Patlola, R; Veerina, KK; Walker, CM; Wyatt, CH, 2007
)
0.34
" 10 miRNAs were commonly altered in serum from dopamine and either fenoldopam or midodrine dosed rats; 18 of these 102 were also altered in mesenteries from rats with drug-induced vascular injury, suggesting their possible utility as peripheral biomarkers."( MicroRNA changes in rat mesentery and serum associated with drug-induced vascular injury.
Chau, NT; Frazier, KS; Mirabile, RC; Scicchitano, MS; Thomas, HC; Thomas, RA, 2012
)
0.62
" We aimed to investigate by color-Doppler ultrasonography the effects of IV administration of FM at this dosage in hypertensive chronic kidney disease (CKD) patients, and verify whether it may induce any systemic hemodynamic alteration."( Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease.
Busca, A; Casasco, M; Di Daniele, N; Ferrannini, M; Manca di Villahermosa, S; Marrone, G; Noce, A; Rovella, V; Sorge, R; Tesauro, M, 2019
)
0.9
" Infusion of FM at such low dosage appears also to be quite safe, even in CKD and hypertensive patients."( Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease.
Busca, A; Casasco, M; Di Daniele, N; Ferrannini, M; Manca di Villahermosa, S; Marrone, G; Noce, A; Rovella, V; Sorge, R; Tesauro, M, 2019
)
0.9
" The following manuscript outlines the commonly used pharmacologic agents for perioperative BP including dosing regimens and adverse effect profiles."( Pharmacologic Control of Blood Pressure in Infants and Children.
Krawczeski, CD; Naguib, A; Simsic, J; Tobias, JD, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
dopaminergic antagonistA drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
vasodilator agentA drug used to cause dilation of the blood vessels.
alpha-adrenergic agonistAn agent that selectively binds to and activates alpha-adrenergic receptors.
dopamine agonistA drug that binds to and activates dopamine receptors.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency33.55210.125919.1169125.8920AID2549; AID2708
acetylcholinesteraseHomo sapiens (human)Potency34.67130.002541.796015,848.9004AID1347398
dopamine D1 receptorHomo sapiens (human)Potency0.00820.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency11.29700.100020.879379.4328AID488773; AID588453; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency2.17120.35487.935539.8107AID624146; AID624170
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID1259243; AID1259247; AID1259381
DNA polymerase III, partialBacillus subtilisPotency26.67951.062114.152826.6795AID485295
hypothetical protein, conservedTrypanosoma bruceiPotency22.38720.223911.245135.4813AID624173
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.39140.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.31490.000229.305416,493.5996AID743075; AID743077; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency10.96400.00108.379861.1304AID1645840
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.32330.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency26.12160.016525.307841.3999AID602332
Histone H2A.xCricetulus griseus (Chinese hamster)Potency77.96720.039147.5451146.8240AID1224845
D(1A) dopamine receptorHomo sapiens (human)Potency0.04320.02245.944922.3872AID488981; AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency0.00670.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency2.81840.01789.637444.6684AID588834
flap endonuclease 1Homo sapiens (human)Potency11.91730.133725.412989.1251AID488816; AID588795
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.84700.000627.21521,122.0200AID743202
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.02390.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)Ki1.92001.92002.94504.3300AID604079
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
D(2) dopamine receptorHomo sapiens (human)Ki0.81000.00000.651810.0000AID63227
DRattus norvegicus (Norway rat)Ki0.00300.00010.610010.0000AID61510
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)1.58000.00100.79948.0000AID62165
D(2) dopamine receptorBos taurus (cattle)Ki0.79000.00000.58366.1000AID62333
D(1A) dopamine receptorHomo sapiens (human)Ki0.04000.00010.836310.0000AID63040
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)EC50 (µMol)0.05700.00820.22540.9500AID63378
D(1A) dopamine receptorHomo sapiens (human)EC50 (µMol)0.01730.00020.47959.5000AID1573447; AID1573449
D(1A) dopamine receptorHomo sapiens (human)Kd0.02800.02801.27634.6000AID61865
D(2) dopamine receptorRattus norvegicus (Norway rat)Kd4.04000.00030.81836.7000AID64790; AID64917; AID64919; AID64925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)KL0.02100.02100.44030.7340AID61996
D(2) dopamine receptorRattus norvegicus (Norway rat)KL1.00000.02300.49531.0000AID64788
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (158)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID189190Central dopaminergic activity was determined by testing compound for its ability to produce contralateral rotation in lesioned rat after ip administration1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID61510Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranes1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes.
AID61356Binding affinity against the Dopamine D1 receptor by the displacement of [3H]fenoldopam from homogenized rat striatum1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID196241Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 1.0 uM dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
AID1573448Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as reversal of Ro 20-1724 mediated decrease in cAMP accumulation after 60 mins by luminescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID64788Low-affinity agonist dissociation constant against striatal Dopamine receptor D21996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID1573449Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as assessed as increase in beta-arrestin-2 recruitment after 60 mins by luminescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1573450Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as assessed as increase in beta-arrestin-2 recruitment after 60 mins by luminescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID59135Effective Dose (ED15) required to decrease renal vascular resistance by 15% in anesthetized dogs administered intravenously1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID63040Affinity towards Dopamine receptor D11998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID234665Renal vasodilator activity was measured between ED20, heart rate (HR) test, and ED15 RVR.1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID604079Non-competitive inhibition of JMJD2E relative to alpha-ketoglutarate2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Inhibitors of histone demethylases.
AID234666Renal vasodilator activity was measured between ED20, measure of mean arterial blood pressure (MABP) test, and ED15 RVR.1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID1573447Agonist activity at human dopamine D1 receptor expressed in CHOK1 cells assessed as reversal of Ro 20-1724 mediated decrease in cAMP accumulation after 60 mins by luminescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID63378Dopamine receptor D1 agonist efficacy was measured with stimulation of dopamine-sensitive rat adenylate cyclase in caudate membranes1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID64790In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID57838Potency was expressed as the average maximum cumulative dose required to decrease renal vascular resistance by 15%1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID63227Affinity towards Dopamine receptor D21998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID167274Ability to relax the electrically stimulated rabbit ear artery was determined1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID61996Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID196243Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 100.0 uM dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID61865Equilibrium dissociation constant against recombinant Dopamine receptor D1A expressed in COS7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID196240Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 0.1 uM dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
AID62333Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D21986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes.
AID61867log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64917In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID64925In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID196242Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 10.0 uM dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID62165Displacement of [3H]spiroperidol from homogenized bovine pituitary Dopamine receptor D21987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64919In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID234667Renal vasodilator activity was measured between ED30, measure in iliac vascular resistance (IVR) test, and ED15 RVR1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID175474Central dopaminergic activity was determined by testing compound for dopamine agonist activity mediated by adenylase cyclase in rat1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID189189Central dopaminergic activity was determined by testing compound for its ability to produce contralateral rotation in lesioned rat after intracerebrally administration1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1345718Human D1 receptor (Dopamine receptors)1994The Journal of biological chemistry, Nov-11, Volume: 269, Issue:45
High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype.
AID1345814Human D4 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (631)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990141 (22.35)18.7374
1990's204 (32.33)18.2507
2000's178 (28.21)29.6817
2010's87 (13.79)24.3611
2020's21 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.90 (24.57)
Research Supply Index6.62 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index95.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials92 (14.00%)5.53%
Reviews87 (13.24%)6.00%
Case Studies12 (1.83%)4.05%
Observational0 (0.00%)0.25%
Other466 (70.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Combination Intra-Renal Infusion of Fenoldopam Mesylate and High Dose Diuretics on Peak Serum Creatinine and Incidence of Renal Replacement Therapy in Patients With Early Acute Kidney Injury [NCT01073189]Phase 40 participants (Actual)Interventional2010-04-30Withdrawn(stopped due to withdrew due to funding)
Fenoldopam Prophylaxis of Splanchnic Organs Underperfusion During Cardiopulmonary Bypass: a Randomized, Controlled Trial. [NCT00747331]Phase 480 participants (Anticipated)Interventional2008-09-30Completed
Paracrine Regulation of Renal Function by Dopamine in Normotensive Humans [NCT01324245]45 participants (Actual)Interventional2002-11-30Completed
Intraoperative Fenoldopam Infusion in Children Requiring Cardiopulmonary Bypass During Cardiac Surgery [NCT00982527]Phase 380 participants (Actual)Interventional2009-09-30Completed
The Effect of Fenoldopam on Renal Function in Solitary Partial Nephrectomy Surgery [NCT00743106]90 participants (Actual)Interventional2002-09-30Terminated(stopped due to Executive committee determined to close study after interim analysis.)
Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study. [NCT00621790]Phase 3667 participants (Actual)Interventional2008-02-29Completed
[NCT00467181]Phase 230 participants (Anticipated)Interventional2005-01-31Completed
Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery [NCT00557219]Phase 360 participants (Actual)Interventional2008-04-30Terminated(stopped due to Main cooperator finished cooperation)
N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery. [NCT00122018]Phase 280 participants Interventional2002-05-31Completed
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses (RMC033) [NCT00592150]Phase 144 participants (Anticipated)Interventional2007-06-30Active, not recruiting
Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial [NCT00286403]Phase 2/Phase 30 participants (Actual)Interventional2008-08-31Withdrawn(stopped due to The study was terminated due to logistics at a local hospital.)
Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial [NCT01690832]Phase 4100 participants (Anticipated)Interventional2012-09-30Active, not recruiting
Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants [NCT02620761]Phase 2/Phase 31 participants (Actual)Interventional2019-02-06Terminated(stopped due to Inability to recruit patients)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00743106 (2) [back to overview]Glomerular Filtration Rate (GFR) Percentage of Change From Baseline
NCT00743106 (2) [back to overview]Postoperative Creatinine (mg/dL)

Glomerular Filtration Rate (GFR) Percentage of Change From Baseline

Our intended primary analysis was to assess the effect of fenoldopam vs placebo on the GFR at post-operative day (POD) 3 with an analysis of covariance adjusting for the baseline GFR. However, because the intervention-by-baseline GFR interaction using GFR at POD 3 as the outcome was significant (P ¼ .006), the analysis of covariance was not valid. We, therefore, used the GFR percentage of change from baseline to POD 3 as the primary outcome. (NCT00743106)
Timeframe: percentage of change from baseline to post-operatively day 3

Interventionpercentage change (Mean)
Placebo-39
Fenoldopam-28

[back to top]

Postoperative Creatinine (mg/dL)

assessed the effect of fenoldopam on creatinine over time (immediately postoperatively and on postoperative day 1, 2, 3, 4) (NCT00743106)
Timeframe: "immediately postoperative, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 4"

,
Interventionmg/dL (Mean)
immediately postoperativepostoperative day 1postoperative day 2postoperative day 3postoperative day 4
Fenoldopam1.372.042.382.462.61
Placebo1.442.142.662.652.76

[back to top]